These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9270781)

  • 1. Losartan decreases hemoglobin in renal transplant recipients.
    Ducloux D; Chalopin JM
    Transplant Proc; 1997 Aug; 29(5):2402-3. PubMed ID: 9270781
    [No Abstract]   [Full Text] [Related]  

  • 2. Angiotensin receptor antagonists: focus on losartan.
    Johnston CI
    Lancet; 1995 Nov; 346(8987):1403-7. PubMed ID: 7475826
    [No Abstract]   [Full Text] [Related]  

  • 3. Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats.
    Linz W; Henning R; Schölkens BA
    J Hypertens Suppl; 1991 Dec; 9(6):S400-1. PubMed ID: 1840203
    [No Abstract]   [Full Text] [Related]  

  • 4. Renal function in one-kidney, one clip sodium-restricted rats: influence of enalapril and losartan.
    Demeilliers B; Jover B; Mimran A
    J Hypertens; 1995 Dec; 13(12 Pt 2):1764-6. PubMed ID: 8903648
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin antagonists.
    Brunner HR; Nussberger J; Waeber B
    Adv Nephrol Necker Hosp; 1993; 22():305-27. PubMed ID: 8427061
    [No Abstract]   [Full Text] [Related]  

  • 6. The advantages of angiotensin II antagonism.
    Burnier M; Waeber B; Brunner HR
    J Hypertens Suppl; 1994 Jul; 12(2):S7-15. PubMed ID: 7965267
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men.
    Goldberg MR; de Mey C; Wroblewski JM; Li Q; Schroeter V; Belz GG
    Clin Pharmacol Ther; 1996 Jan; 59(1):72-82. PubMed ID: 8549037
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of chronic treatment with losartan and enalaprilat on [3H]-norepinephrine release from isolated atria of Wistar-Kyoto and spontaneously hypertensive rats.
    Foucart S; Patrick SK; Oster L; de Champlain J
    Am J Hypertens; 1996 Jan; 9(1):61-9. PubMed ID: 8834708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Blockade of the renin-angiotensin system in heart failure in conscious dogs.
    Murakami M; Suzuki H; Naitoh M; Matsumoto A; Kageyama Y; Tsujimoto G; Saruta T
    J Hypertens; 1995 Dec; 13(12 Pt 1):1405-12. PubMed ID: 8866902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renal effects of angiotensin II receptor blockade and angiotensin-converting enzyme inhibition in healthy subjects.
    Burnier M; Brunner HR
    Exp Nephrol; 1996; 4 Suppl 1():41-6. PubMed ID: 9001896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benefit of angiotensin II receptor blockade in the treatment of posttransplant polycythemia in renal transplant recipients.
    Kupin W; Venkat KK; Goggins M; Abouljoud M; Escobar F; Mozes M
    Transplant Proc; 1997; 29(1-2):207-8. PubMed ID: 9122965
    [No Abstract]   [Full Text] [Related]  

  • 12. Effect of angiotensin II type 1 receptor antagonist on urinary prostaglandin E2 excretion following furosemide in rats.
    Fujimura A; Sudoh T; Ebihara A
    Life Sci; 1994; 55(9):707-11. PubMed ID: 8065233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass.
    Lafayette RA; Mayer G; Park SK; Meyer TW
    J Clin Invest; 1992 Sep; 90(3):766-71. PubMed ID: 1522231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ACE inhibitors, angiotensin II antagonists and cough. The Losartan Cough Study Group.
    Ramsay LE; Yeo WW
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S51-4. PubMed ID: 8583482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [New antihypertensive drugs on various phases of study].
    Kuramochi M
    Nihon Rinsho; 1992 May; 50 Suppl():34-8. PubMed ID: 1355131
    [No Abstract]   [Full Text] [Related]  

  • 16. Losartan in post-transplant erythrocytosis.
    Conlon PJ; Smith SR; Butterly DW; Brennan DC
    Nephrol Dial Transplant; 1996 Dec; 11(12):2524-5. PubMed ID: 9017645
    [No Abstract]   [Full Text] [Related]  

  • 17. Losartan, an angiotensin-II receptor antagonist, reduces hematocrits in kidney transplant recipients with posttransplant erythrocytosis.
    Klaassen RJ; van Gelder T; Rischen-Vos J; Deinum J; Man in't Veld AJ; Weimar W
    Transplantation; 1997 Sep; 64(5):780-2. PubMed ID: 9311722
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of an AT1 receptor antagonist, an ACE inhibitor and a calcium channel antagonist on cardiac gene expressions in hypertensive rats.
    Kim S; Ohta K; Hamaguchi A; Yukimura T; Miura K; Iwao H
    Br J Pharmacol; 1996 Jun; 118(3):549-56. PubMed ID: 8762077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Converting enzyme inhibition modulates sympathetic neurotransmission in vivo via multiple mechanisms.
    Schwieler JH; Kahan T; Nussberger J; Hjemdahl P
    Am J Physiol; 1993 Apr; 264(4 Pt 1):E631-7. PubMed ID: 8386457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Haemodynamic effects of losartan and the endothelin antagonist, SB 209670, in conscious, transgenic ((mRen-2)27), hypertensive rats.
    Gardiner SM; March JE; Kemp PA; Mullins JJ; Bennett T
    Br J Pharmacol; 1995 Oct; 116(4):2237-44. PubMed ID: 8564254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.